Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 7/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.47 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25633284 | 0.91 | KMT2A (0.55) | KMT2ATP53RXFP1THRBNPC1 | |
| SCHEMBL25633294 | 0.89 | TP53 (0.67) | KMT2ATP53RXFP1THRBNPC1 | |
| SCHEMBL25633348 | 0.89 | TP53 (0.67) | KMT2ATP53RXFP1THRBNPC1 | |
| SCHEMBL25633277 | 0.88 | NPC1 (0.66) | KMT2ATP53THRBNPC1SAE1 | |
| SCHEMBL25361185 | 0.81 | NLRP3 (0.51) | KMT2ATP53RXFP1THRBNPC1 | |
| SCHEMBL25633326 | 0.79 | TP53 (0.56) | KMT2ATP53RXFP1THRBNPC1 | |
| SCHEMBL25633392 | 0.77 | NLRP3 (0.69) | KMT2ATP53RXFP1THRBSAE1 | |
| SCHEMBL25633383 | 0.76 | TP53 (0.60) | KMT2ATP53RXFP1THRB | |
| SCHEMBL25633350 | 0.76 | TP53 (0.70) | KMT2ATP53RXFP1THRBNPC1 | |
| SCHEMBL14564344 | 0.74 | BRD4 (0.49) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183249-A1 | NEW TRIAZINOINDOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
| US-20230183249-A1 | NEW TRIAZINOINDOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183249-A1 | NEW TRIAZINOINDOLE COMPOUNDS | NLRP3, NLRP1, PYCARD | KMT2A 3866/4885TP53 1754/4885RXFP1 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.